Introduction
Glutamate and dopamine reciprocally modulate neurotransmission in the nigrostriatal, mesocortical, and mesolimbic systems. [1] [2] [3] [4] These signaling systems are conspicuously affected by Parkinson's disease (PD). 5 Poisoning dopaminergic neurons in the substantia nigra of animal models leads to increased expression of metabotropic glutamate receptors in the striatum. 6 Pharmacological inhibition of Group 1 glutamatergic receptors in animal models of PD produced by poisoning dopaminergic neurons seems to be neuroprotective. 7 Nonclinical studies and several clinical trials have suggested that Group 1 glutamatergic antagonists and negative allosteric modulators provide symptomatic relief of the dyskinesias associated with PD. [8] [9] [10] These observations suggest that the expression of Group 1 glutamate receptor proteins might be abnormally regulated in PD disease. This could make glutamate receptors interesting targets for novel drugs. It could also make them candidates for pharmacodynamic biomarkers of response to neuroprotective treatments that do not target the glutaminergic system directly, and despite the fact that the ultimate goal of treatment is to regenerate the dopaminergic system. Group 1 glutamate receptors include the metabotropic glutamate receptor 5 (mGluR5). Some histopathological evaluations of brain specimens from clinical cases of PD and from PD animal models have reported upregulation of mGlur5 receptors in brain cells along with elevated levels of aggregated alpha-Synuclein, 11, 12 a well-known hallmark of PD. Other studies have not, 13 or reported the opposite. 14 Relatively small, single site trials of PD have been conducted with a high affinity, specific radiopharmaceutical for mGluR5. However, the results have either not been fully reported out in the literature yet, 15 or their online summaries suggest the findings were complicated. 16 These observations suggest that a clearer understanding of differential mGluR5 expression between patients with PD and matched controls could provide important disease-relevant insights.
Fluorine-18 (
is one of several radiopharmaceuticals for noninvasively quantifying mGluR5 with positron emission tomography (PET). 17 [ 18 F]FPEB is a potent and highly specific antagonist. [18] [19] [20] [21] [22] It has several characteristics shared by many useful biomarkers, 23, 24 including its relative ease of synthesis, 25, 26 physical half-life, and a best-in-class kinetic energy associated with its positron. The within subjects repeatability of its nondisplaceable binding potential (BP ND ) 27 is outstanding by neuroimaging standards, at an average of only about 5-8% in striatal and mesocortical regions known to be affected by PD. 28 Establishing the value of any biomarker requires many steps. The primary aim of this pilot study was to explore whether or not there are meaningful differences in the regional binding potentials of [ 18 F]FPEB in patients with PD and healthy volunteers (HVs). Showing a difference would not be sufficient to show [ 18 F]FPEB is a useful response biomarker. However, the failure to show a difference would suggest that mGluR5 is not worth pursuing as a pharmacodynamic biomarker. Secondary objectives included exploring relationships between estimates of regional cerebral mGluR5 and dopamine transporter (DaT) density.
Methods

Human Volunteers
This study was approved by the institutional review board of Weill Cornell Medical College. All participants gave informed consent, which was documented in writing. Primary screening was conducted by a senior neurologist specializing in movement disorders (CH). For subjects with PD, selection was based on the inclusion and exclusion criteria described in the UK Brain Bank Criteria. 29 HVs could not have any of the corresponding problems. All subjects were required to be older than 40, have an unremarkable medical history except for benign hypertension or hyperlipidemia, and an unremarkable physical examination. All clinical laboratory studies had to be within normal limits, including a complete blood cell count, and tests of liver and renal function. Urinalysis, urine pregnancy tests when applicable, and urine toxicology screens had to be negative.
Potential participants who passed the initial screening procedures then underwent a secondary screening procedure with magnetic resonance imaging (MRI) of the head that included standard clinical sequences.
Those who could tolerate the MRI procedure and were found to be free of another CNS disease that could cause parkinsonism underwent a final screening procedure with a DaT tracer, Carbon-11 ( Patients were required to have typical DaT scan signs of PD, 33 or their participation was terminated. HVs were required to be free of any imaging signs of abnormal DaT density, such as decreased binding in the posterior putamen.
PET Imaging
PE2i served a dual purpose: (1) as a tertiary screening procedure and (2) as another way to characterize the severity of the disease. The radiopharmaceutical formulation was administered as a slow bolus over 60 seconds via a pump (Graseby 3400, Smith Medical LTD, UK). Simultaneously, a dynamic emission scan was started in 3-dimensional list mode. Reconstructions for estimating the BP ND consisted of 22 frames with progressive durations (4 × 15, 4 × 30, 4 × 60, 2 × 120, 8 × 300, and 1 × 600 seconds). Total emission scan duration was 60 minutes.
[ 18 F]FPEB was administered as a fast bolus through an intravenous catheter that was shown to be patent by manipulating the drip rate of normal saline with an inclined roller clamp immediately prior to injection. Simultaneously, a dynamic emission scan was started in 3-dimensional list mode. Reconstructions consisted of 30 frames with progressive durations (4 × 15, 4 × 30, 3 × 60, 2 × 120, 5 × 240, and 12 × 300 seconds). Total emission scan duration was 90 minutes.
All PET/CT acquisitions were performed using an LSO time-of-flight whole body PET scanner (mCT, Siemens/CTI, Knoxville, TN, USA). 34 Images were reconstructed in a 400 × 400 matrix with a voxel size of 1.082 × 1.082 × 2.025 mm 
Image Analysis
Dynamic data were motion corrected with PMODv3.5 (PMOD Technologies Ltd., Zurich Switzerland). 35 Cerebellar white matter was prespecified as a reference region. 36 The Logan reference tissue model was implemented to calculate BP ND . Standardized uptake value ratios (SUVr) for measurement of tracer distribution were calculated using cerebellar white matter as a reference region at 60-90 minutes. Volume of interests (VOIs) were defined by automated segmentations of MRI data using Freesurfer v8.0 (Martinos Center for Biomedical Imaging, Charlestown, MA, USA). The following VOIs were measured: caudate, putamen, thalamus, hippocampus amygdala, cortical gray matter, cortical white matter, and cerebellar white matter. It might be noteworthy that the dorsal striatum, where mGluR5 is localized, could not be semiautomatically segmented from the ventral striatum, where it is not expressed.
Statistical Analysis
As described above, most of the literature in animal models seems to suggest that mGluR5 should be upregulated in patients with PD. However, as noted, the actual data in humans seem complicated. And, the potential confounds of factors such as age, duration of the disease, and treatment with dopaminergic agonists made the use of one-tailed hypothesis testing seem precarious. For these reasons, the analysis was agnostic about whether mGluR5 would be upregulated or downregulated in this sample.
The descriptive statistics were performed using SPSS (IBM Corp. Version 22.0. Armonk, NY, USA). In all analyses, the statistical significance (α level) was set at P < .05.
Results
Subjects
The final sample consisted of nine PD patients and eight HVs. There were seven men and two women in the patient group with a mean age of 62 ± 7 years (range: 54-71). There were seven men and one woman in the control group with a mean age of 50 ± 4 years (range: 47-67). Estimations of the PE2i BP ND values showed essentially no overlap in any basal ganglia region of these patients versus controls, as shown in Figure 1 . Z-scores ([BP ND of each patientmean BP ND of HVs]/SD of HVs) were calculated for each VOI. The bilateral putamen was 3.5 standard deviations (SD) below the mean of HVs, and the bilateral caudate was 2.9 SD below the mean of HVs.
PE2i Scans of DaT
FPEB Scans of mGluR5
PD patients were administered an average of 184 ± 19 MBq (5.0 ± .3 mCi) of [ 18 F]FPEB. HVs received 182 ± 15 MBq (4.9 ± .4 mCi). The differences between groups were not significant (P = .74), and there were no outliers.
No scans were confounded by clinical or technical factors, such as excessive subject movement or instrumentation failure. The distribution of FPEB was consistent with prior reports on the regional cerebral distribution of mGluR5, as shown in Figure 2 . 5, 37, 38 Time activity curves of PE2i and FPEB are shown in Figure 3 .
The BP ND of FPEB in HV was compared with SUVr to support the use of cerebellar white matter as a reference region. The correlations between the two measures were robust (r = .94) and significant P < .00001; Fig 4) . SUVr values were smaller than BP ND in all ROIs except in the caudate and amygdala of a single subject. .26 (P = .31) .06 (P = .82) -.51 (P = .04) .02 (P = .94) .17 (P = .51) .12 (P = .28)
Correlations were based on nine patients with Parkinson's disease and eight healthy volunteers. BP ND = binding potential, nondisplaceable; FPEB = the mGluR5 radiopharmaceutical used in this study; PE2i = a radiopharmaceutical for dopamine transporters; TH = bilateral thalamus; CAU = bilateral caudate; PU = bilateral putamen; HIP = bilateral hippocampus; AMY = bilateral amygdala; ALL = includes every subject and every volume of interest.
BP ND of FPEB in PD patients was significantly increased by 23% ± 22% in the bilateral putamen (P = .01), by 26% ± 23% in the bilateral hippocampus (P = .01), and by 21% ± 23% in the bilateral amygdala (P = .02) (Fig 5) . However, differences in the thalamus and caudate did not reach statistical significance. Calculated z-scores in the putamen were 2.0 standard deviations above the mean of HVs.
Correlation between PE2i and FPEB BP ND
Relationships between the regional BP ND of PE2i and FPEB were explored. A significant correlation was found in the putamen (r = -.51, P = .04). As shown in Table 1 , no other significant correlations were found within this small sample.
Discussion
The findings suggest that mGluR5 is significantly upregulated in striatal and mesotemporal gray matter regions affected by PD. The difference between groups measured in this study was about 20%, which is encouraging. A delta of 20% is at least twofold higher than the coefficient of variation (CV) for [ 18 F]FPEB in the volumes of most potential interest, which tend to be less than 10%, and almost fourfold greater than the CV in the putamen, which is only about 5%. 22 The true biological differences between groups are likely even greater than this imaging study suggests for several reasons. No corrections for volume averaging were applied, and there were no attempts to separate the dorsal from the ventral striatum. Volume averaging dilutes the dorsal striatum, which contains mGluR5 receptors, with the ventral striatum, which does not. This might partially explain why the findings with [ 18 F]FPEB were not as striking as the separation between groups with [ 11 C]PE2i. DaTs are located in both the dorsal striatum, where they are associated with D2-like receptors and mGluR5, as well as the ventral striatum, where they are associated with D1-like receptors and mGluR1, but not mGluR5. 4 While techniques for separating the dorsal and ventral striatum have been reported, 39 we did not risk manipulating the image analysis in this way because there was no reason to think this sort of volume averaging would not affect both groups equally. Mean age is another factor that could indicate the group differences were underestimated in this study. Although the selection criteria for age were the same for patients and controls, random chance led to the patients being older. This is interesting because mGluR5 seems to decrease with age in most regions of interest. 40 43, 44 there are lingering concerns. The same factors that make DaT tracers such good diagnostic agents could limit their dynamic range, and as a consequence, their unique value as early response markers. Dopamine reuptake proteins seem remarkably downregulated before any symptoms emerge. 44 As a consequence, it might be that drug effects on DaT might not become apparent until clinical signs and symptoms have improved so much that no imaging biomarker is necessary. Weaker discriminatory tracers, such as [
18 F]FPEB, could prove to be better proxies for the early effects of neuroprotective drugs. Although this pilot study only started the prerequisite ground work for qualifying a quantitative imaging biomarker, the results seem to justify moving forward with the validation process for pharmacodynamic markers of response in longitudinal trials of neuroprotective drugs.
